UPDATE 2-British midcaps post weekly losses on Brexit woes, dour outlook
* AstraZeneca to run new global trial of COVID-19 vaccine - report
* JD Sports among worst performing bluechips this week
* Drugmaker Indivior underperforms midcaps for the week (Updates to close)
By Devik Jain and Ambar Warrick
Nov 27 (Reuters) - Domestically-oriented British midcap stocks rose slightly on Friday, but marked their first weekly loss this month as frictions in the Brexit process and a gloomy economic outlook due to the coronavirus weighed on sentiment.
The mid-cap FTSE 250 .FTMC rose 0.3% and lost 0.2% for the week, while the blue-chip FTSE 100 .FTSE ended the day and the week a touch higher.
The European Union and Britain said there were still substantial differences over a Brexit trade deal, with three main issues of contention - fishing, state aid and how to resolve any future disputes.
The EU chief negotiator prepared to travel to London in a last-ditch attempt to avoid a tumultuous divorce, with just five weeks left until the deadline for UK's exit. talks will be held over the weekend—but this is not yet the last possible moment for a deal, and a deal can (by EU tradition) only occur at the last possible moment," Paul Donovan, chief economist of UBS Global Wealth Management said.
Appetite for locally-focussed stocks was battered through the week by updates from the finance and health ministers over the COVID-19 pandemic's economic impact, while doubts over the efficacy of a leading vaccine candidate also weighed.
A Bloomberg report said AstraZeneca AZN.L was likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, amid questions over the results of its late-stage study. individual stocks, retailer JD Sports Fashion JD.L was among the worst performing blue-chip stocks for the week in the face of strict restrictions on activity even after the end of a nationwide lockdown.
Drugmaker Indivior INDV.L underperformed its midcap peers for the week with a 23.9% loss after it was slapped with a 1.07 billion pound ($1.43 billion) claim by its former owner Reckitt Benckiser RB.L .
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.
Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or